Eledon Pharmaceuticals (ELDN) Return on Capital Employed (2014 - 2026)
Eledon Pharmaceuticals (ELDN) posted Return on Capital Employed of 57.45% for Q1 2026, up 18.21% on a QoQ basis from 70.25% in Q3 2025, and down 896.0% year-over-year from 7.22% in Q1 2025.
Eledon Pharmaceuticals (ELDN) Return on Capital Employed (2014 - 2026) Analysis & Trends
Eledon Pharmaceuticals' Return on Capital Employed history runs 13 years deep, the most recent figure standing at 57.45% for Q1 2026.
- Quarterly Return on Capital Employed fell 896.0% year-over-year to 57.45% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 57.45% (down 896.0% YoY) and the FY2025 annual result came in at 11.25%, up 6926.0% from the prior year.
- Return on Capital Employed was 57.45% for Q1 2026 at Eledon Pharmaceuticals, up from 70.25% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 23.14% in Q1 2022 and bottomed at 109.27% in Q1 2023.
- A 5-year average of 59.49% and a median of 53.25% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed plunged 8613 bps — and 2024, when it jumped 5628 bps.
- Eledon Pharmaceuticals' Return on Capital Employed stood at 77.09% in 2022, then surged by 37 bps to 48.49% in 2023, then fell by 8 bps to 52.51% in 2024, then plunged by 34 bps to 70.25% in 2025, then grew by 18 bps to 57.45% in 2026.
- Business Quant data shows ELDN's Return on Capital Employed at 57.45% in Q1 2026, 70.25% in Q3 2025, and 63.06% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Eledon Pharmaceuticals | 5.43 Mn | -105.66 Mn | - | -57.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.45% |
| Sep 30, 2025 | -70.25% |
| Jun 30, 2025 | -63.06% |
| Mar 31, 2025 | -48.49% |
| Dec 31, 2024 | -52.51% |
| Sep 30, 2024 | -53.52% |
| Jun 30, 2024 | -49.57% |
| Mar 31, 2024 | -52.99% |
| Dec 31, 2023 | -48.49% |
| Sep 30, 2023 | -92.71% |
| Jun 30, 2023 | -101.23% |
| Mar 31, 2023 | -109.27% |
| Dec 31, 2022 | -77.09% |
| Sep 30, 2022 | -26.82% |
| Jun 30, 2022 | -25.22% |
| Mar 31, 2022 | -23.14% |
| Dec 31, 2021 | -21.76% |
| Sep 30, 2021 | -19.15% |
| Jun 30, 2021 | -15.90% |
| Mar 31, 2021 | -12.66% |